Transdermal composition of n-n-5-4-(aminoiminomethyl)phenyl-1-oxopentyl-l-.alpha.-aspartyl-l-phenylalanine or its esters and their pharmaceutically acceptable salts
CA 2176462 A1 · Owner: Feigen, Larry P. · Inventors: Feigen, Larry P.; Griffin, Martin John
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is for, pharmaceutical compositions and a method of use for the transdermal delivery of N-N-5-4(aminoiminomethyl)phenyl-1-, oxopentyl-L-.alpha.-aspartyl-L-phenylalanine or its esters and their pharmaceutically acceptable salts which are useful as platelet aggregation inhibitors. In formula (I) R can, be independently hydrogen or alkyl having 1 to 6 carbon atoms.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 24, 1994. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 24, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 24, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.